A prospective, randomised, open, crossover patient preference study comparing oral immediate release and transdermal oxybutynin in overactive bladder patients

ISRCTN ISRCTN03265047
DOI https://doi.org/10.1186/ISRCTN03265047
Secondary identifying numbers 2006-001-Oxy-OAB-Skin-Oxy
Submission date
31/01/2007
Registration date
22/03/2007
Last edited
30/07/2009
Recruitment status
Stopped
Overall study status
Stopped
Condition category
Urological and Genital Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Christian Hampel
Scientific

Johannes Gutenberg-Universität Mainz
Department of Urology
Langenbeckstr. 1
Mainz
55131
Germany

Phone +49 (0)6131-17-2310
Email hampel@urologie.klinik.uni-mainz.de

Study information

Study designProspective, randomised, open, 2 x 6 - week crossover, single-centre subject preference trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Scientific title
Study acronymOxy-OAB-Skin-Oxy
Study objectivesThe primary endpoint is treatment preference of subjects who will be asked at the end of the 2nd treatment period. The preference will be checked for its plausibility in an end-of-period satisfaction rating (6 = very satisfied, 0 = very dissatisfied). Treatment satisfaction will be assessed at the end of each period of the cross over. The total score on the satisfaction visual analog scale of the two treatment periods will be compared to express preference.
Ethics approval(s)In progress as of 2 February 2007
Health condition(s) or problem(s) studiedSubjects with overactive bladder (OAB)
InterventionAs of 29/07/09 the status of this trial was updated to 'stopped' due to poor recruitment. The decsion to terminate the trial was made on 25/11/2008, the date of last patient out (LPO) was on 17/07/2009

Test product: Kentera™ TDS 3,9 mg/24h, transdermal patch vs Reference therapy: Oxybutynin ratiopharm® 5 mg, tablets
Intervention typeOther
Primary outcome measurePrimary efficacy endpoint will be the personal preference of the subject after both treatment phases. The preference will be checked for its plausibility in an end-of-period satisfaction rating (total of scores of final list of questions: 6 = very satisfied, 0 = very dissatisfied)
Secondary outcome measures1. Cognitive abilities during treatment with orally administered Oxybutynin versus transdermal administration of Oxybutynin measured by CNS tests (Trail Making Test and Wechsler Memorial Scale-Revised)
2. Quality of life assessed with ”King´s Health Questionnaire”
3. Severity of urinary incontinence episodes estimated in pad test at V1, V3, V4 and V6
4. Reports of adverse event (AE)/serious adverse event (SAE) in terms of severity and frequency
5. Frequency of micturition assessed in a 3 day diary in every treatment period
6. Urinary incontinence episodes assessed in a 3 day diary in every treatment period
7. Degree of severity of incontinence episodes estimated in Sandvik Index and documented at subject visits
8. Urgency frequency assessed in a 3 day diary in every treatment period
9. Treatment satisfaction will be assessed with a satisfaction questionnaire at the end of each treatment period
Overall study start date01/03/2007
Completion date01/12/2007
Reason abandoned (if study stopped)Participant recruitment issue

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participantsIt is planned to enroll 80 patients in the trial.
Key inclusion criteriaSubjects meeting all of the following criteria will be considered for admission to the trial:
1. Male or female (18 – 80 years) suffering from OverActive Bladder (OAB)
2. Symptoms of OAB as defined by:
a. Urgency frequency ≥7 /week
b. Urinary urgency incontinence (> 7 UIE/week)
c. Urodynamically proven detrusor instability
3. Women must be surgically sterile, be postmenopausal or must agree to use effective contraception during treatment phases (i.e. contraceptions with a failure ratio of < 1%/ year are implants, injection preparations, combined oral contraceptives, intrauterine device [e.g. hormone spiral] or vasectomy of the partner)
4. Negative urine pregnancy test for women capable of child-bearing within 24 hours before administration of the first dose medication at V1
5. Signed and dated informed consent of the subject must be available before start of any specific trial procedures
6. Ability of subject to understand character and individual consequences of clinical trial
Key exclusion criteriaSubjects presenting with any of the following criteria will not be included in the trial:
1. Pregnancy and lactation
2. History of hypersensitivity to the investigational medicinal product or to any drug with similar chemical structure or to any excipient present in the pharmaceutical form of the investigational medicinal product
3. Subjects with significant urinary obstruction as measured during cystometry (e.g. prostatic hyperplasia, stricture of urethra), severe gastro-intestinal condition (e.g. toxic megacolon, severe ulcerative colitis, intestinal atony, bowel obstruction), myasthenia gravis or uncontrolled narrow-angle glaucoma
4. Refractory to antimuscarine treatment: Subjects having experienced no benefit from previous treatment with oral or transdermal oxybutynin
5. Subjects with hiatus hernia and reflux oesophagitis
6. Subjects with acute prostatitis
7. Subjects with urinary frequency or nocturia due to cardiac or renal insufficiency and without urgency
8. Subjects with tachyarrhythmia (pulse > 100/min)
9. Subjects with Parkinsons`s disease or Alzheimer`s disease or other cerebral diseases
10. Subjects with cognitive impairment, not able to understand content and aim of the trial
11. Medical or psychological condition that would not permit completion of the trial or signing of informed consent
12. Participation in other clinical trials and observation period of competing trials, respectively
13. Subjects who have previously been enrolled in the trial
Date of first enrolment01/03/2007
Date of final enrolment01/12/2007

Locations

Countries of recruitment

  • Germany

Study participating centre

Johannes Gutenberg-Universität Mainz
Mainz
55131
Germany

Sponsor information

Johannes Gutenberg-Universität Mainz, Fachbereich Medizin (Germany)
University/education

c/o Prof J Thüroff
Executive center
Langenbeckstr. 1
Mainz
55131
Germany

Phone +49 (0)6131 17 7183
Email thueroff@urologie.klinik.uni-mainz.de
ROR logo "ROR" https://ror.org/023b0x485

Funders

Funder type

Industry

UCB Farchim S.A. (Switzerland)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan